Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.40 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.39 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.34 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8296936 | 0.98 | — | — | |
| SCHEMBL23197652 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL4779651 | 0.91 | SPHK1 (0.47) | CA1SPHK1SPHK2FDPSOPRM1 | |
| SCHEMBL27863219 | 0.91 | CA1 (0.50) | CA1SPHK1SPHK2NOS3NOS1 | |
| SCHEMBL10185778 | 0.88 | SPHK1 (0.48) | CA1SPHK1SPHK2FDPSOPRM1 | |
| SCHEMBL12566014 | 0.88 | SPHK1 (0.48) | CA1SPHK1SPHK2FDPSOPRM1 | |
| SCHEMBL172766 | 0.88 | SPHK1 (0.48) | CA1SPHK1SPHK2FDPSOPRM1 | |
| SCHEMBL28842476 | 0.88 | SPHK1 (0.48) | CA1SPHK1SPHK2FDPSOPRM1 | |
| SCHEMBL172831 | 0.88 | SPHK1 (0.48) | CA1SPHK1SPHK2FDPSOPRM1 | |
| SCHEMBL2698591 | 0.88 | SPHK1 (0.48) | CA1SPHK1SPHK2FDPSOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459607-B1 | HYBRID COPOLYMER COMPOSITIONS FOR PERSONAL CARE APPLICATIONS | NOURYON CHEMICALS INT BV (NL) | 2021-04-14 | — | — | EP | disclosed |
| EP-2459606-B1 | HYBRID COPOLYMER COMPOSITIONS | NOURYON CHEMICALS INT BV (NL) | 2020-10-21 | — | — | EP | disclosed |
| US-9988526-B2 | Hybrid dendrite copolymers, compositions thereof and methods for producing the same | AKZO NOBEL CHEMICALS INTERNATIONAL B.V. (NL) | 2018-06-05 | — | — | US | disclosed |
| US-9321873-B2 | Hybrid copolymer compositions for personal care applications | AKZO NOBEL N.V. (NL) | 2016-04-26 | — | — | US | disclosed |
| EP-2773320-B1 | HYBRID DENDRITE COPOLYMERS, COMPOSITIONS THEREOF AND METHODS FOR PRODUCING THE SAME | AKZO NOBEL CHEMICALS INT BV (NL) | 2016-02-03 | — | — | EP | disclosed |
| US-9109068-B2 | Hybrid copolymer compositions | AKZO NOBEL N.V. (NL) | 2015-08-18 | — | — | US | disclosed |
| US-20140256880-A1 | Hybrid dendrite copolymers, compositions thereof and methods for producing the same | NOURYON CHEMICALS INTERNATIONAL B.V. (NL) | 2014-09-11 | — | — | US | disclosed |
| EP-2773320-A1 | HYBRID DENDRITE COPOLYMERS, COMPOSITIONS THEREOF AND METHODS FOR PRODUCING THE SAME | Akzo Nobel Chemicals International B.V. (NL) | 2014-09-10 | — | — | EP | disclosed |
| US-20130292611-A1 | HYBRID MIXTURES FOR GAS HYDRATE INHIBITION APPLICATIONS | AKZO NOBEL CHEMICALS INTERNATIONAL B.V. (NL) | 2013-11-07 | — | — | US | disclosed |
| EP-2658945-A1 | HYBRID MIXTURES FOR GAS HYDRATE INHIBITION APPLICATIONS | Akzo Nobel Chemicals International B.V. (NL) | 2013-11-06 | — | — | EP | disclosed |
| WO-2013064647-A1 | HYBRID DENDRITE COPOLYMERS, COMPOSITIONS THEREOF AND METHODS FOR PRODUCING THE SAME | AKZO NOBEL CHEMICALS INTERNATIONAL B.V. (NL) | 2013-05-10 | — | — | WO | disclosed |
| WO-2012089654-A1 | HYBRID MIXTURES FOR GAS HYDRATE INHIBITION APPLICATIONS | AKZO NOBEL CHEMICALS INTERNATIONAL B.V. (NL) | 2012-07-05 | — | — | WO | disclosed |
| EP-2459606-A1 | HYBRID COPOLYMER COMPOSITIONS | Akzo Nobel N.V. (NL) | 2012-06-06 | — | — | EP | disclosed |
| EP-2459607-A1 | HYBRID COPOLYMER COMPOSITIONS FOR PERSONAL CARE APPLICATIONS | Akzo Nobel N.V. (NL) | 2012-06-06 | — | — | EP | disclosed |
| US-20120134942-A1 | Hybrid copolymer compositions for personal care applications | AKZO NOBEL N.V. (NL) | 2012-05-31 | — | — | US | disclosed |
| US-20120128608-A1 | Hybrid copolymer compositions | AKZO NOBEL N.V. (NL) | 2012-05-24 | — | — | US | disclosed |
| WO-2011017223-A1 | HYBRID COPOLYMER COMPOSITIONS FOR PERSONAL CARE APPLICATIONS | AKZO NOBEL N.V. (NL) | 2011-02-10 | — | — | WO | disclosed |
| WO-2011014783-A1 | HYBRID COPOLYMER COMPOSITIONS | AKZO NOBEL N.V. (NL) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120128608-A1 | Hybrid copolymer compositions | EPHX2, PUF60, ELOVL6 | CA2 3726/4885OPRM1 1512/4885CA1 1469/4885 |
| US-20120134942-A1 | Hybrid copolymer compositions for personal care applications | CUTA, MMS19, POLH | CA2 4431/4885OPRM1 3703/4885CA1 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.